Table 4. Treatment-related adverse events.
| Adverse event | FS group (n=47), n (%) | FT group (n=45), n (%) | |||||
|---|---|---|---|---|---|---|---|
| Grade 1–2 | Grade 3 | Grade 4 | Grade 1–2 | Grade 3 | Grade 4 | ||
| Hematologic | |||||||
| Anemia | 21 (44.7) | 2 (4.3) | 0 | 24 (53.3) | 3 (6.7) | 0 | |
| Decreased white blood count | 2 (4.3) | 1 (2.1) | 0 | 5 (11.1) | 2 (4.4) | 0 | |
| Decreased platelet count | 8 (17.0) | 0 | 0 | 10 (22.2) | 1 (2.2) | 0 | |
| Hepatic toxicity | 7 (14.9) | 1 (2.1) | 0 | 6 (13.3) | 2 (4.4) | 0 | |
| Nonhematologic | |||||||
| Decreased appetite | 12 (25.5) | 1 (2.1) | 0 | 17 (37.8) | 4 (8.9) | 0 | |
| Diarrhea | 11 (23.4) | 1 (2.1) | 0 | 12 (26.7) | 0 | 0 | |
| Hand-foot syndrome | 6 (12.8) | 1 (2.1) | 0 | 8 (17.8) | 2 (4.4) | 0 | |
| Oral mucositis | 5 (10.6) | 0 | 0 | 7 (15.6) | 0 | 0 | |
| Rash | 5 (10.6) | 0 | 1 (2.1) | 2 (4.4) | 0 | 0 | |
| Hypothyroidism | 6 (12.8) | 1 (2.1) | 0 | 1 (2.2) | 0 | 0 | |
| Fatigue | 13 (27.7) | 2 (4.3) | 0 | 15 (33.3) | 3 (6.7) | 0 | |
| Pneumonitis | 2 (4.3) | 0 | 0 | 0 | 0 | 0 | |
| Proteinuria | 4 (8.5) | 0 | 0 | 3 (6.7) | 0 | 0 | |
| Secondary hypertension | 5 (10.6) | 2 (4.3) | 0 | 4 (8.9) | 1 (2.2) | 0 | |
FS, fruquintinib plus sintilimab; FT, fruquintinib plus TAS-102; TAS-102, trifluridine and tipiracil.